锦欣生殖医疗集团有限公司是一家投资控股公司，主要提供试管受精（IVF）服务。该公司通过其子公 司主要提供辅助生殖服务、管理服务、流动手术中心设施服务、辅助医疗服务、妇产儿科医疗服务，以 及从事医疗消耗品及设备销售业务。该公司主要在中国及美国提供服务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，1月15日南向资金减持278.45万股锦欣生殖（01951.HK）。近5个交易日中，获南向资金 减持的有4天，累计净减持1349.4万股。近20个交易日中，获南向资金减持的有13天，累计净减持2050.9 万股。截至目前，南向资金持有锦欣生殖（01951.HK）14.44亿股，占公司已发行普通股的52.35%。 ...

证券之星消息，1月7日南向资金减持367.45万股锦欣生殖（01951.HK）。近5个交易日中，获南向资金 减持的有4天，累计净减持701.7万股。近20个交易日中，获南向资金减持的有14天，累计净减持2917.7 万股。截至目前，南向资金持有锦欣生殖（01951.HK）14.56亿股，占公司已发行普通股的52.78%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 锦欣生殖医疗集团有限公司是一家投资控股公司，主要提供试管受精（IVF）服务。该公司通过其子公 司主要提供辅助生殖服务、管理服务、流动手术中心设施服务、辅助医疗服务、妇产儿科医疗服务，以 及从事医疗消耗品及设备销售业务。该公司主要在中国及美国提供服务。 ...

锦欣生殖医疗集团有限公司是一家投资控股公司，主要提供试管受精（IVF）服务。该公司通过其子公 司主要提供辅助生殖服务、管理服务、流动手术中心设施服务、辅助医疗服务、妇产儿科医疗服务，以 及从事医疗消耗品及设备销售业务。该公司主要在中国及美国提供服务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，12月30日南向资金减持51.35万股锦欣生殖（01951.HK）。近5个交易日中，获南向资金 减持的有4天，累计净减持598.1万股。近20个交易日中，获南向资金减持的有12天，累计净减持1582.05 万股。截至目前，南向资金持有锦欣生殖（01951.HK）14.62亿股，占公司已发行普通股的53.0%。 ...

锦欣生殖医疗集团有限公司是一家投资控股公司，主要提供试管受精（IVF）服务。该公司通过其子公 司主要提供辅助生殖服务、管理服务、流动手术中心设施服务、辅助医疗服务、妇产儿科医疗服务，以 及从事医疗消耗品及设备销售业务。该公司主要在中国及美国提供服务。 证券之星消息，12月22日南向资金增持307.0万股锦欣生殖（01951.HK）。近5个交易日中，获南向资金 减持的有2天，累计净减持14.75万股。近20个交易日中，获南向资金增持的有11天，累计净增持877.5万 股。截至目前，南向资金持有锦欣生殖（01951.HK）14.66亿股，占公司已发行普通股的53.16%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - Southbound funds increased their holdings in Jinxin Fertility (01951.HK) by 4.53 million shares on December 10, indicating a positive sentiment towards the company despite recent fluctuations in trading volume [1] Group 1: Southbound Fund Activity - In the last 5 trading days, southbound funds reduced their holdings on 4 days, with a total net reduction of 16.03 million shares [1] - Over the past 20 trading days, southbound funds increased their holdings on 14 days, resulting in a total net increase of 18.23 million shares [1] - Currently, southbound funds hold 1.465 billion shares of Jinxin Fertility, accounting for 53.1% of the company's total issued ordinary shares [1] Group 2: Company Overview - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, ambulatory surgical center facilities, auxiliary medical services, and maternal and pediatric medical services [1] - Jinxin Fertility operates mainly in China and the United States, also engaging in the sale of medical consumables and equipment [1]

Core Viewpoint - Southbound funds have reduced their holdings in Jinxin Fertility (01951.HK) by 11.989 million shares on December 9, indicating a trend of net selling over recent trading days [1] Group 1: Southbound Fund Activity - In the last 5 trading days, southbound funds have reduced their holdings for 5 days, with a total net reduction of 24.8715 million shares [1] - Over the past 20 trading days, there have been 13 days of net increases in holdings by southbound funds, totaling a net increase of 9.3238 million shares [1] - Currently, southbound funds hold 1.46 billion shares of Jinxin Fertility, accounting for 52.94% of the company's issued ordinary shares [1] Group 2: Company Overview - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers assisted reproductive services, management services, ambulatory surgical center facility services, auxiliary medical services, obstetrics and pediatrics medical services, as well as sales of medical consumables and equipment [1] - Jinxin Fertility operates mainly in China and the United States [1]

证券之星消息，12月5日南向资金减持237.65万股锦欣生殖（01951.HK）。近5个交易日中，获南向资金 减持的有3天，累计净减持811.7万股。近20个交易日中，获南向资金增持的有14天，累计净增持3211.68 万股。截至目前，南向资金持有锦欣生殖（01951.HK）14.74亿股，占公司已发行普通股的53.43%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-12-05 | 14.74亿 | -237.65万 | -0.16% | | 2025-12-04 | 14.76亿 | -450.15万 | -0.30% | | 2025-12-03 | 14.81亿 | -431.25万 | -0.29% | | 2025-12-02 | 14.85 亿 | 17.10万 | 0.01% | | 2025-12-01 | 14.85 亿 | 290.25万 | 0.20% | 锦欣生殖医疗集 ...

Core Viewpoint - Southbound funds have significantly increased their holdings in Jinxin Reproductive Medicine (01951.HK), indicating strong investor interest in the company [1] Group 1: Shareholding Changes - On December 1, southbound funds increased their holdings by 2.9025 million shares, representing a 0.20% change [2] - Over the past five trading days, there has been a cumulative net increase of 27.119 million shares held by southbound funds [1][2] - In the last 20 trading days, southbound funds have increased their holdings on 15 occasions, with a total net increase of 48.7178 million shares [1] Group 2: Current Holdings - As of now, southbound funds hold a total of 1.485 billion shares of Jinxin Reproductive Medicine, accounting for 53.83% of the company's issued ordinary shares [1][2] Group 3: Company Overview - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and sales of medical consumables and equipment, mainly in China and the United States [2]

Group 1 - Southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 6.2985 million shares on November 26, 2025, marking a 0.43% change [1][2] - Over the past five trading days, there have been five days of net increases in holdings, totaling 20.795 million shares [1][2] - In the last 20 trading days, there were 13 days of net increases, amounting to 31.1263 million shares [1][2] Group 2 - As of now, southbound funds hold 1.474 billion shares of Jinxin Reproductive Medicine, representing 53.44% of the company's total issued ordinary shares [1][2] - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and sales of medical consumables and equipment, mainly in China and the United States [2]

Core Insights - Southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 611,000 shares on November 24, 2025, marking a consistent trend of net increases over recent trading days [1] - Over the past 5 trading days, there has been a cumulative net increase of 11.76 million shares, while in the last 20 trading days, the total net increase reached 12.71 million shares [1] - As of now, southbound funds hold 1.458 billion shares of Jinxin Reproductive Medicine, accounting for 52.84% of the company's total issued ordinary shares [1] Summary by Category Trading Activity - On November 24, 2025, total shares held reached 1.458 billion, with a change of 611,000 shares, reflecting a 0.04% increase [2] - On November 21, 2025, total shares held were 1.457 billion, with a change of 630,000 shares, also a 0.04% increase [2] - On November 20, 2025, total shares held were 1.456 billion, with a change of 3.183 million shares, indicating a 0.22% increase [2] - On November 19, 2025, total shares held were 1.453 billion, with a change of 3.168 million shares, also a 0.22% increase [2] - On November 18, 2025, total shares held were 1.450 billion, with a change of 4.170 million shares, reflecting a 0.29% increase [2] Company Overview - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and maternal and pediatric medical services [2] - Jinxin Reproductive Medicine operates mainly in China and the United States [2]